Galectin Therapeutics Inc.
GALT
We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$23M
▲ +34.5% YoY
Op. Margin
–
ROIC
-18695.82%
▲ +1474.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$15M
▲ +42.8% YoY
Op. Cash Flow (TTM)
-$15M
▲ +42.8% YoY
Net Debt
-$12M
Net Cash Position
Cash & Equiv.
$12M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with GALT
Held by ETFs
GALT is in 5 US ETFs. The largest of them, with GALT's weight in each:
Galectin Therapeutics (GALT) in two numbers
Questions about Galectin Therapeutics
Does Galectin Therapeutics (GALT) pay a dividend?
No. Galectin Therapeutics (GALT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in GALT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GALT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.